These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30157797)

  • 41. Comparative pharmacokinetics of the three echinocandins in ICU patients.
    Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
    J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.
    Yamada SM; Tomita Y; Yamaguchi T; Matsuki T
    J Med Case Rep; 2016 Nov; 10(1):316. PubMed ID: 27821139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods.
    Cantón E; Pemán J; Hervás D; Espinel-Ingroff A
    J Antimicrob Chemother; 2013 Apr; 68(4):864-8. PubMed ID: 23228935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L; Shoham S; Vazquez J; Reboli A; Betts R; Barron MA; Schuster M; Judson MA; Revankar SG; Caeiro JP; Mangino JE; Mushatt D; Bedimo R; Freifeld A; Nguyen MH; Kauffman CA; Dismukes WE; Westfall AO; Deerman JB; Wood C; Sobel JD; Pappas PG
    Clin Infect Dis; 2014 May; 58(9):1219-26. PubMed ID: 24550378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients.
    Chan TS; Gill H; Hwang YY; Sim J; Tse AC; Loong F; Khong PL; Tse E; Leung AY; Chim CS; Lie AK; Kwong YL
    Ann Hematol; 2014 Mar; 93(3):493-8. PubMed ID: 23949318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain].
    García-Vargas M; Casado MA; Mir N; Barrueta JA
    Farm Hosp; 2012; 36(4):207-15. PubMed ID: 22118764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study on the comparative activity of echinocandins on murine gut colonization by Candida albicans.
    Maraki S; Hamilos G; Dimopoulou D; Andrianaki AM; Karageorgiadis AS; Kyvernitakis A; Lionakis S; Kofteridis DP; Samonis G
    Med Mycol; 2015 Aug; 53(6):597-602. PubMed ID: 25980001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use and outcome of empiric echinocandins in critically ill patients.
    Ylipalosaari P; Ala-Kokko TI; Koskenkari J; Laurila JJ; Ämmälä S; Syrjälä H
    Acta Anaesthesiol Scand; 2021 Aug; 65(7):944-951. PubMed ID: 33481252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
    García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.
    Grau S; Pozo JC; Romá E; Salavert M; Barrueta JA; Peral C; Rodriguez I; Rubio-Rodríguez D; Rubio-Terrés C
    Clinicoecon Outcomes Res; 2015; 7():527-35. PubMed ID: 26508881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
    Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
    Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical hepatotoxicity associated with antifungal agents.
    Kyriakidis I; Tragiannidis A; Munchen S; Groll AH
    Expert Opin Drug Saf; 2017 Feb; 16(2):149-165. PubMed ID: 27927037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.